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MicroRNAs (miRNAs) are a recently discovered class of B18–24 nucleotide RNA molecules that negatively regulate target mRNAs.
All studied multicellular eukaryotes utilise miRNAs to regulate basic cellular functions including proliferation, differentiation, and death.
It is now apparent that abnormal miRNA expression is a common feature of human malignancies. In this review, we will discuss how
miRNAs influence tumorigenesis by acting as oncogenes and tumour suppressors.
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MicroRNAs (miRNAs) were first discovered in the early 1990s by
Ambros, Ruvkun, and co-workers while studying development in
the nematode Caenorhabditis elegans (Lee et al, 1993; Wightman
et al, 1993). Their analyses of genes that control developmental
timing revealed that lin-14 was necessary for the differentiation of
specific cell lineages and lin-4 might be a trans-acting negative
regulator of lin-14. Subsequently, it was determined that lin-4
encodes a 22-nucleotide noncoding RNA which negatively
regulates the translation of lin-14 by directly base pairing to
complementary sites within its 30-untranslated region (30 UTR).
Since very few examples of regulation of an mRNA by a naturally
occurring antisense RNA had been described in eukaryotes, this
form of regulation was generally considered a fascinating, but
likely worm-specific, oddity. Seven years later, another small
regulatory RNA, let-7, was identified as an additional regulator of
developmental timing in C. elegans (Reinhart et al, 2000).
Strikingly, both the sequence and temporal expression pattern of
let-7 were conserved in a wide variety of animals (Pasquinelli et al,
2000), suggesting a more general role for small RNAs in gene
regulation. Nevertheless, the broad significance of these findings
was not fully appreciated until hundreds of similar small RNAs
were identified in C. elegans, Drosophila, and mammals by
molecular cloning and bioinformatics analyses in 2001 (reviewed
in Bartel, 2004). These newly discovered B18–24 nucleotide RNAs
were termed microRNAs (miRNAs). Since their initial description,
more than 3000 miRNAs have been identified in animals, plants,
and viruses. In the human genome, more than 300 miRNAs have
been discovered, and the estimated number of miRNA genes is as
high as 1000 (Bentwich et al, 2005; Berezikov et al, 2005). As a
group, miRNAs are estimated to regulate 30% of genes in the
human genome (Lewis et al, 2005).
In addition to providing critical functions during normal
development and cellular homeostasis, it has become increasingly
clear that abnormalities in miRNA activity contribute to human
disease pathogenesis. In particular, an important role for miRNAs
in the development of cancer has emerged. In this review, we will
discuss the functions of cancer-relevant miRNAs that regulate
cellular proliferation, death, and tumorigenesis.
miRNA BIOGENESIS AND FUNCTION
MicroRNAs are initially transcribed by RNA polymerase II (pol II)
as long primary transcripts known as primary-miRNAs (pri-
miRNAs). Like other pol II transcripts, these RNAs are capped,
polyadenylated, and are usually several kilobases in length
(reviewed in Kim, 2005). Approximately half of pri-miRNAs
appear to lack significant open reading frames and are likely
noncoding RNAs. Nevertheless, these transcripts are often spliced
and many miRNAs are located within their intronic segments.
Alternatively, a significant fraction of miRNAs (B40%) are found
within introns of known protein-coding genes (Rodriguez et al,
2004). Additionally, miRNAs are frequently clustered such that a
single pri-miRNA contains multiple miRNA sequences.
Within the pri-miRNA, the miRNA itself is contained within a
B60–80 nucleotide sequence that can fold back on itself to form a
stem-loop hairpin structure. MicroRNA hairpins are recognised
and excised from pri-miRNAs in the nucleus (Figure 1) by the
microprocessor complex, which includes the RNase III enzyme
drosha and its binding partner DGCR8 (Kim, 2005). The excised
miRNA hairpins, referred to as pre-miRNAs, contain a two
nucleotide 30 overhang characteristic of RNase III cleavage
products. Pre-miRNAs are rapidly exported to the cytoplasm by
the nuclear export factor exportin 5 which uses Ran-GTP as a
cofactor (Yi et al, 2003; Bohnsack et al, 2004; Lund et al, 2004).
Further cytoplasmic processing by dicer, a second RNase III
enzyme, produces an B18–24 nucleotide duplex. This fully
processed duplex is incorporated in an ATP-independent manner
into a large protein complex known as the RNA-induced silencing
complex, or RISC, which includes as core components the
Argonaute proteins (Ago1–4 in humans). Only one strand of the
miRNA duplex remains stably associated with RISC. This strand
becomes the mature miRNA. The opposite strand, known as the
passenger strand or miRNA*, is disposed of through two
alternative mechanisms. When miRNAs are loaded into RISC
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target mRNAs, the passenger strand may be cleaved. Alternatively,
RISC containing any Ago protein may remove the passenger
strand via a bypass mechanism that does not require cleavage and
likely involves duplex unwinding (Gregory et al, 2005; Matranga
et al, 2005; Rand et al, 2005).
MicroRNAs act as guides that direct RISC to target mRNAs that
are subsequently cleaved or translationally silenced (reviewed in
Bartel, 2004). The degree of complementarity between an miRNA
and its target determines the mechanism of regulation. When an
miRNA and an mRNA exhibit perfect complementarity, the target
mRNA is cleaved by RISC. This appears to be the predominant
mechanism through which miRNAs function in plants. Imperfect
base pairing between an miRNA and its target, as occurs with most
C. elegans, Drosophila, and mammalian miRNAs, leads to
translational silencing of the target. However, imperfectly com-
plementary miRNAs can also reduce the abundance of target
mRNAs to varying degrees (He and Hannon, 2004).
EARLY CLUES THAT miRNAs REGULATE
CANCER-RELEVANT PATHWAYS
Malignant cell growth is typified by loss of cellular identity,
enhanced proliferation, and dysregulated cell death. Early clues
that miRNAs were important in regulating these cancer-relevant
cellular phenotypes came from genetic screens in C. elegans and
Drosophila. As mentioned above, the first miRNA identified, lin-4,
controls the timing of developmental events in C. elegans. Loss-of-
function of lin-4 results in the abnormal differentiation of specific
cell lineages and the reiteration of embryonic cell types in later
stages of development (Lee et al, 1993). These abnormalities are
reminiscent of tumours which are caused by a failure to fully
execute a programme of differentiation. For example, in many
haematologic malignancies, a block in differentiation causes
immature cells to accumulate with pathologic consequences.
In Drosophila, overexpression of the Bantam miRNA causes
overgrowth of wing and eye tissue. It was subsequently demon-
strated that Bantam stimulates cell proliferation and prevents
apoptosis at least in part through negative regulation of the
proapoptotic gene hid (Brennecke et al, 2003). Another Drosophila
miRNA, miR-14, was identified through its ability to suppress cell
death. Flies harbouring a deletion of this miRNA were found to
have an increased expression of an apoptotic effector caspase,
Drice, which has a putative miR-14 target site (Xu et al, 2003).
However, direct regulation of Drice by miR-14 remains to be
demonstrated. In another study, antisense-mediated inhibition of
the miR-2/6/11/13/308 family in Drosophila embryos was demon-
strated to induce widespread apoptosis. These miRNAs were
subsequently shown to regulate the proapoptotic factors hid, grim,
reaper, and sickle (Leaman et al, 2005).
miRNA DYSREGULATION IN CANCER
A more direct link between miRNA function and cancer
pathogenesis is supported by studies examining the expression
of miRNAs in clinical samples. The first study documenting
abnormalities in miRNA expression in tumour samples focused on
B-cell chronic lymphocytic leukaemia (B-CLL). Deletion of
chromosome 13q14 is the most frequent chromosomal abnorm-
ality in this disorder and it has been postulated that a tumour
suppressor gene resides in this region. Croce and co-workers
demonstrated that this tumour suppressor activity is likely
provided by two miRNAs, miR-15a and miR-16-1, which are
localised in the minimally deleted region and are frequently
deleted or downregulated in CLL patients (Calin et al, 2002). More
recently, these investigators found that a specific expression
signature consisting of 13 miRNAs, including miR-15a and miR-
16-1, was associated with disease progression in CLL (Calin et al,
2005).
More than half of miRNAs are located at sites in the human
genome that are frequently amplified, deleted, or rearranged in
cancer, suggesting that miRNA abnormalities play a broad role in
cancer pathogenesis (Calin et al, 2004). Also consistent with this
notion is the observed dysregulation of miRNA expression in
diverse cancer subtypes including Burkitt’s lymphoma (Metzler
et al, 2004), colorectal cancer (Michael et al, 2003), lung cancer
(Takamizawa et al, 2004), breast cancer (Iorio et al, 2005), and
glioblastoma (Chan et al, 2005).
Recently, Golub and co-workers used a bead-based flow
cytometric method to profile 217 mammalian miRNAs across a
large panel of samples representing diverse human tissues and
tumours (Lu et al, 2005). They found that miRNA profiles were
highly informative, reflecting the developmental lineage and
differentiation state of the tumours. MicroRNA profiles were used
to identify the tissue origin of poorly differentiated tumours with
greater accuracy than profiles constructed using B16000 mRNAs.
Furthermore, tumours within the same lineage harbouring distinct
chromosomal rearrangements were found to exhibit distinct
miRNA expression profiles. Thus, the developmental history of a
tumour is reflected in its miRNA expression pattern.
Irrespective of cell type, more than half of the miRNAs
examined in the Golub study were expressed at significantly lower
levels in tumours compared with normal tissues. This likely
reflects a role for miRNAs in terminal differentiation and the
relatively incomplete differentiation status of cancer cells. Con-
sistent with this hypothesis, inducing differentiation of a myeloid
leukaemia cell line with all-trans retinoic acid increased the
expression of many miRNAs. A similar induction of miRNA
expression was also observed in primary human haematopoietic
progenitor cells undergoing erythroid differentiation.
The emerging view from these studies is that dysregulation of
miRNA expression is a frequent occurrence in diverse types of
cancer. These findings highlight the potential utility of miRNA
profiling for diagnostic and prognostic applications. These studies
also highlight a need for more direct functional analyses of the
roles of miRNAs in regulating pathways relevant to tumour
pathogenesis. These types of experiments are now beginning to be
carried out, as described below.
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Figure 1 The biogenesis and functions of cancer-associated human
miRNAs. A simplified schematic of miRNA biogenesis is shown.
MicroRNAs are initially transcribed by RNA polymerase II (Pol II) and
sequentially processed by drosha and dicer (see text for details).
MicroRNAs with tumour suppressing or oncogenic properties are shown
with their experimentally validated targets.
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MicroRNAs with proproliferative and antiapoptotic activity would
likely promote oncogenesis and thus may be overexpressed in
cancer cells. The most comprehensively studied example of an
miRNA locus with these properties is the mir-17 cluster, consisting
of six miRNAs: miRs-17-5p, -18, -19a, -19b, -20, and -92. This
miRNA cluster is located on human chromosome 13q31, a region
that is frequently amplified in several types of lymphoma and solid
tumours (Ota et al, 2004). In a recent study, He et al (2005) found
that miRNAs from this cluster are highly expressed in B-cell
lymphoma samples and cell lines. To directly interrogate the
tumorigenic properties of these miRNAs, they utilised Em-Myc
transgenic mice, a model of B-cell lymphoma in which expression
of the proto-oncogene c-Myc is driven by the immunoglobulin
heavy-chain enhancer. c-Myc encodes a helix-loop-helix transcrip-
tion factor that is abnormally active in a large fraction of human
malignancies. Elevated c-Myc expression accelerates cell prolifera-
tion and growth and, in some settings, induces apoptosis. Em-Myc
transgenic mice develop B-cell lymphomas relatively late in life
(4–6 months of age) and with incomplete penetrance. When a
truncated form of the mir-17 cluster (lacking miR-92) was
introduced into haematopoietic stem cells from these mice, disease
onset was dramatically accelerated. Whereas Em-Myc lymphomas
are highly apopotic, the miRNA-expressing lymphomas show a
high mitotic index without extensive apoptosis, suggesting that
these miRNAs act primarily by suppressing cell death. Interest-
ingly, when each of the miRNAs of the mir-17 cluster was
individually coexpressed with c-Myc, none accelerated tumour
formation, suggesting that the oncogenic effect requires a
cooperative interaction between the miRNAs in the cluster.
Moreover, no increased lymphomagenesis was observed after
expressing 96 different single miRNAs in this model, demonstrat-
ing the specificity of the mir-17 cluster finding.
While a functional interaction between the mir-17 cluster and
Myc was being explored in the Em-Myc animals, independent work
by O’Donnell et al (2005) discovered that these miRNAs were
directly regulated at the transcriptional level by c-Myc. In multiple
cellular models, induction of c-Myc expression correlated with
induction of the mir-17 cluster. Furthermore, c-Myc was found to
bind directly to the genomic locus encoding these miRNAs to
activate their transcription. The authors went on to show that two
miRNAs in this cluster, miR-17-5p and miR-20, regulate the
translational efficiency of the proproliferative/proapoptotic tran-
scription factor E2F1. Interestingly, E2F1 is known to be
transcriptionally activated by c-Myc (Fernandez et al, 2003). Since
high expression of E2F1 is sufficient to induce apoptosis in some
settings, simultaneous transcriptional activation by c-Myc and
dampening of translational efficiency by the mir-17 cluster may
tune E2F1 activity such that cell death is disfavoured and
proliferation is promoted. This hypothesis is consistent with the
decreased apoptosis observed in the Em-Myc miRNA-expressing
tumours.
Amplification of the mir-17 cluster and overexpression of these
miRNAs has more recently been observed in lung cancers and in
particular small-cell lung cancer (Hayashita et al, 2005). In a lung
cancer cell line, overexpression of the entire mir-17 cluster, but not
individual miRNAs from the cluster, accelerated cell proliferation.
These findings further document the oncogenic properties of this
group of miRNAs.
Another miRNA with an apparent antiapoptotic function is
miR-21. This miRNA was found to be overexpressed in
glioblastoma tumour tissues and cell lines (Chan et al, 2005).
High expression of this miRNA was also observed in breast cancer
tissue (Iorio et al, 2005). Inhibition of miR-21 in glioblastoma cell
lines using 20-O-methyl antisense oligonucleotides, which are
known to inhibit miRNA function, resulted in caspase activation
and increased apoptosis (Chan et al, 2005).
ANTIPROLIFERATIVE/PROAPOPTOTIC miRNAs
MicroRNAs with antiproliferative and proapoptotic activity are
likely to function as tumour suppressor genes and thus may be
underexpressed in cancer cells. The family of let-7 miRNAs
represents a clear example of this. The let-7 family consists of a
group of highly conserved miRNAs in multiple species including C.
elegans, Drosophila, and vertebrates. let-60/RAS was recently
identified as a target of let-7 in C. elegans (Johnson et al, 2005).
This regulation appears to be conserved in humans where three
RAS genes, known to be potent oncogenes, have also been
demonstrated to be directly regulated by human let-7. Since RAS
dysregulation is a key oncogenic event in lung cancer, loss of let-7
may contribute to pathogenesis in this disorder. Indeed, let-7 is
generally expressed at low levels in cancerous lung tissue
compared to normal tissue and low expression of this miRNA
correlates with shorter postoperative lung cancer survival (Taka-
mizawa et al, 2004). Furthermore, in samples from three lung
cancer patients, RAS protein levels, but not RAS mRNA levels,
were inversely correlated with let-7 levels, consistent with miRNA-
mediated translational repression (Johnson et al, 2005). Expression
of let-7 in lung cancer cell lines directly suppresses growth in vitro,
further documenting the tumour suppressing activity of this
miRNA (Takamizawa et al, 2004).
miR-15a and miR-16-1 represent additional miRNAs with likely
tumour suppressing activity. As mentioned above, these miRNAs
are located on human chromosome 13 in a region frequently
deleted in B-CLL. Cimmino et al (2005) identified a conserved
target site for miR-15a and miR-16-1 in the 30 UTR of BCL2, a
potent inhibitor of cell death. Consistent with a regulatory
interaction between these miRNAs and this gene, the levels of
miR-15a and miR-16-1 are inversely correlated with Bcl2 protein
levels in samples from CLL patients. Furthermore, overexpression
of miR-15a and miR-16-1 in a leukaemic cell line results in
decreased Bcl2 protein expression, activation of the intrinsic
apoptosis pathway, and ultimately cell death. Thus, loss of these
miRNAs may contribute to elevated Bcl2 expression and
pathologic cell survival in B-CLL.
miRNAs IN CELL CYCLE PROGRESSION AND
STEM CELL MAINTENANCE
Both cancer cells and stem cells share an ability to divide
continuously without undergoing senescence. Additionally, evi-
dence supports the existence of ‘cancer stem cells’ that may be
important in the genesis of certain types of cancers including
leukaemia and solid tumours. Because of the importance of these
cells in normal and pathophysiologic states, there is growing
interest in elucidating the mechanisms that confer the unique
properties of these cells. Recent experiments in which components
essential for miRNA biogenesis were disrupted in flies suggest that
miRNAs may play a role in stem cell maintenance. Drosophila with
a null mutation of dicer-1 (dcr-1), which is required for miRNA
processing, exhibited abnormalities in germline stem cell (GSC)
function (Hatfield et al, 2005). Specifically, dcr-1-deficient GSCs
inappropriately activated the G1/S cell cycle checkpoint, suggesting
that miRNAs normally act to promote continuous cell cycle
progression. This cell cycle delay was specific to GSCs and did not
occur in other tissues such as imaginal discs. Reduction of
expression of Dacapo (Dap), a Drosophila homologue of the p21/
p27 family of cyclin-dependent kinase inhibitors, partially rescued
the dcr-1 deficiency phenotype. Dap is predicted to be regulated by
multiple miRNAs and expression of a Dap transgene lacking these
putative miRNA-binding sites mimicked the phenotype of dcr-1
loss-of-function. Taken together, these data suggest that miRNAs
normally function to suppress Dap expression in GSCs, thus
allowing cell-cycle progression.
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It is now well established that miRNAs play essential roles in many
basic physiologic processes including proliferation, differentiation,
and apoptosis. Abnormalities in miRNA function impinge upon
the normal regulation of these pathways and thus influence
tumorigenesis. Undoubtedly, the growing interest in this class of
regulatory RNAs will lead to continued classification of miRNA
expression in cancer samples and the identification of new
miRNAs that may act as oncogenes and tumour suppressors.
The key to understanding the roles of these molecules in cancer
will be identifying and validating the critical targets responsible for
the phenotypic effects of miRNA loss- or gain-of-function.
Although bioinformatics approaches have produced exhaustive
lists of putative targets, verifying these regulatory interactions and
determining which are the critical targets in a given tissue or
tumour remains arduous.
Another potential challenge for future studies relates to the
probable tissue-specific functions of some miRNAs. The function
of a given miRNA is dictated by the milieu of targets that are
expressed in a given cell type. Thus, an miRNA that regulates both
proproliferative and antiproliferative targets may act as a tumour
suppressor in some cancers and an oncogene in others, depending
on which targets are driving tumorigenesis. One example of this
may be the mir-17 cluster. The evidence that these miRNAs have
oncogenic activity was presented earlier in this review. Never-
theless, the chromosomal locus encompassing these miRNAs is
known to undergo loss-of-heterozygosity in hepatocellular carci-
noma (Lin et al, 1999), suggesting that these miRNAs may have
tumour suppressor activity in this type of cancer. Additionally,
many proproliferative targets are predicted to be downregulated by
these miRNAs. Future studies are necessary to determine if these
and other miRNAs have cell-type-specific effects on cell prolifera-
tion and death.
Although we are at an early stage in our understanding of the
roles of miRNAs in cancer, the importance of these molecules in
this disease process are clear. Undoubtedly, continued efforts to
delineate miRNA function in physiologic and pathophysiologic
states will reveal novel insights into normal cellular and
developmental biology and the mechanisms that are disrupted
when these processes go awry.
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